Pimagedine: a novel therapy for diabetic nephropathy

Expert Opinion on Investigational Drugs
Emaad Abdel-Rahman, W Kline Bolton

Abstract

Hyperglycaemia is directly involved in causing long-term diabetic complications. The non-enzymatic glycation of proteins, yielding irreversible advanced glycation end products and advanced glycation end products-derived protein crosslinking, participates in the development of diabetic complications, such as diabetic nephropathy. Diabetic nephropathy is becoming a major medical problem with increasing numbers of these patients progressing to end stage renal disease, thus requiring renal replacement therapy. While several interventions may slow the development and progression of diabetic nephropathy, there is no effective treatment to prevent or reverse the disease. Pimagedine (aminoguanidine HCl) has been shown to be an effective agent in reducing the severity of the structural and functional alterations associated with experimental diabetic nephropathy. Preliminary studies suggest a beneficial effect of pimagedine in treating patients with diabetic nephropathy. In summary, these observations support a role for advanced glycation end products inhibitors, like pimagedine, in the management of diabetic nephropathy, either alone or in combination with other therapies.

References

Jan 1, 1992·Diabetologia·D Edelstein, M Brownlee
Oct 1, 1991·Metabolism: Clinical and Experimental·E N Ellis, B H Good
Jan 1, 1989·Critical Reviews in Food Science and Nutrition·J O'Brien, P A Morrissey
May 19, 1988·The New England Journal of Medicine·M BrownleeH Vlassara
Nov 22, 1994·Proceedings of the National Academy of Sciences of the United States of America·H VlassaraM Steffes
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Aug 1, 1993·Diabetic Medicine : a Journal of the British Diabetic Association·N E Cameron, M A Cotter
Mar 9, 1993·Biochemical Pharmacology·L Stjernborg, L Persson
Aug 16, 1996·The Journal of Biological Chemistry·J Bubeck WardenburgP R Findell
Jun 10, 1997·Proceedings of the National Academy of Sciences of the United States of America·T KoschinskyH Vlassara
Oct 7, 1997·Clinical and Experimental Pharmacology & Physiology·M E CooperG Jerums
May 16, 1998·Proceedings of the National Academy of Sciences of the United States of America·B H WolffenbuttelB I Lévy
Jan 16, 1999·Journal of the American Society of Nephrology : JASN·D D Fanestil
Apr 13, 1999·Biochemical and Biophysical Research Communications·R G KhalifahB G Hudson
Jun 5, 1999·The American Journal of Cardiology·S M Grundy
Jun 12, 1999·Dementia and Geriatric Cognitive Disorders·M GolebiowskiA Pfeffer
Sep 14, 1999·The American Journal of Medicine·A I Vinik

❮ Previous
Next ❯

Citations

Apr 18, 2009·Cellular and Molecular Neurobiology·Wei-Bing XuLian-Shun Jia
Apr 13, 2011·Cellular and Molecular Neurobiology·Mohsen AlipourMaryam Pourheidar
Oct 19, 2011·Journal of General Internal Medicine·Emaad M Abdel-RahmanAlaa S Awad
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Paolo MenèFrancesco Pugliese
Jun 19, 2014·Néphrologie & thérapeutique·Victor GueutinHassane Izzedine
Dec 3, 2014·Primary Care·Samuel SnyderAlan Turner
Apr 1, 2009·Expert Opinion on Drug Metabolism & Toxicology·Carol Wadham, Arduino A Mangoni
Apr 19, 2005·Expert Opinion on Investigational Drugs·Kei FukamiJosephine M Forbes
Jan 3, 2016·European Journal of Pharmacology·Cláudia de Souza FerreiraMaria Rita Rodrigues
Jan 8, 2013·The Medical Clinics of North America·Deanna S KaniaBrian M Shepler
Apr 29, 2010·Brain Research·Zhong-Kai FanYu-Qiang Zhang
Feb 9, 2010·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Faruk Turgut, Warren Kline Bolton
May 2, 2015·Journal of Ethnopharmacology·Leilei WangYibin Feng
Oct 25, 2008·Neuroscience Letters·Fan DiWang Yun-Jie
Jun 20, 2006·British Journal of Pharmacology·Vincent ChanLindsay Brown
Oct 22, 2003·Archives of Biochemistry and Biophysics·Sara VasanHank Founds
Jul 11, 2006·Medical Hypotheses·Mark F McCarty
Apr 12, 2005·Advances in Chronic Kidney Disease·Mark E Williams, Katherine R Tuttle
Aug 26, 2011·European Journal of Pharmacology·Vinicius F CarvalhoPatrícia M R E Silva
Nov 25, 2005·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Shi-Fang YanAnn Marie Schmidt
Jul 20, 2017·Analytical Chemistry·Anna Voloshenko RossinOvadia Lev
Jul 10, 2019·Dalton Transactions : an International Journal of Inorganic Chemistry·Jing XiangTai-Chu Lau
May 19, 2017·Clinical Science·Marie FrimatEric Boulanger
Aug 23, 2020·Antioxidants·Guillermo García-Díez, Nelaine Mora-Diez
Nov 1, 2015·Archives of Pharmacal Research·Meha Fatima AftabRizwana Sanaullah Waraich
Mar 18, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Serhii VakalTiina A Salminen
Apr 23, 2003·Journal of the American Society of Nephrology : JASN·Thoralf WendtAnn Marie Schmidt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.